Luisa Petraccia

ORCID: 0000-0001-7171-3428
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hepatitis C virus research
  • Therapeutic Uses of Natural Elements
  • Liver Disease Diagnosis and Treatment
  • Myofascial pain diagnosis and treatment
  • Chronic Lymphocytic Leukemia Research
  • Systemic Lupus Erythematosus Research
  • Heparin-Induced Thrombocytopenia and Thrombosis
  • Hydrogen's biological and therapeutic effects
  • Hepatitis B Virus Studies
  • Gastroesophageal reflux and treatments
  • Gastrointestinal Tumor Research and Treatment
  • COVID-19 Clinical Research Studies
  • Immunodeficiency and Autoimmune Disorders
  • SARS-CoV-2 and COVID-19 Research
  • Gastrointestinal motility and disorders
  • Medical and Biological Sciences
  • Atherosclerosis and Cardiovascular Diseases
  • Vasculitis and related conditions
  • Vascular Malformations and Hemangiomas
  • Galectins and Cancer Biology
  • Gastrointestinal disorders and treatments
  • Inflammatory Myopathies and Dermatomyositis
  • Gout, Hyperuricemia, Uric Acid
  • Renal function and acid-base balance
  • Liver Diseases and Immunity

Sapienza University of Rome
2004-2024

Policlinico Umberto I
2005-2024

University of Florence
2016-2023

Azienda Ospedaliero-Universitaria Careggi
2018-2019

Fondazione Italiana Fegato
2016

Terma (Denmark)
2009

Hepatitis C virus (HCV)‐associated mixed cryoglobulinemia (MC) vasculitis commonly regresses upon eradication, but conventional therapy with pegylated interferon and ribavirin yields approximately 40% sustained virologic responses (SVR). We prospectively evaluated the efficacy safety of sofosbuvir‐based direct‐acting antiviral therapy, individually tailored according to latest guidelines, in a cohort 44 consecutive patients HCV‐associated MC. In two MC had evolved into an indolent lymphoma...

10.1002/hep.28753 article EN Hepatology 2016-08-03

Summary Background Cryoglobulinaemic vasculitis (CV) is a lymphoproliferative disorder related to hepatitis C virus ( HCV ) infection; anti‐viral therapy the first therapeutic option. CV can be incapacitating, compromising patients’ quality of life (QoL). In controlled study, interferon‐based was associated with lower virological response in vasculitic patients than without vasculitis. Limited, uncontrolled data on direct‐acting anti‐virals are available. Aim To evaluate safety, clinical...

10.1111/apt.14845 article EN Alimentary Pharmacology & Therapeutics 2018-06-28

Functional disorders of the biliary tract involve gallbladder and sphincter Oddi cause pain and/or digestive troubles. In this context, in addition to pharmacological treatments, an important role is played by use sodium-sulphate sulphate-bicarbonate mineral waters that, because their composition into ions macro trace elements, can stimulate release or modulate activity some neurohumoral regulators process. We want do a study on effects hydropinotherapy with...

10.7417/ct.2014.1761 article EN PubMed 2014-01-01

Direct-acting antivirals (DAAs) usually lead to improvement/remission of cryoglobulinemic vasculitis (CV), although symptoms may persist/recur after a sustained virological response (SVR). We evaluated hematological and genetic markers in patients with HCV-SVR without persisting/recurring early predict the CV outcome.Ninety-eight HCV-CV were prospectively enrolled DAA-induced SVR: Group A: 52 complete clinical response; B: 46 symptom maintenance/recurrence. Monoclonal B-cell lymphocytosis,...

10.1002/hep.31804 article EN cc-by-nc Hepatology 2021-03-15

Background: New direct-acting antiviral drugs can eradicate hepatitis C virus (HCV) infection in over 90% of patients and even reduce the risk complications advanced fibrosis/cirrhosis. The aims this study were to evaluate (1) changes fibrosis during after treatment (2) incidence hepatocarcinoma mortality various stages.Methods: This is a longitudinal monocentric prospective study. Blood instrumental examinations evaluated at baseline, end therapy, 1 2 years following treatment.Results: Two...

10.1080/03007995.2019.1691517 article EN Current Medical Research and Opinion 2019-11-08

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified in China, December 2019 determines COronaVIrus Disease 19 (COVID-19). Whether or not the virus was present Italy earlier first autochthonous COVID-19 case diagnosed is still uncertain. We aimed to identify anti-SARS-CoV-2 antibodies sera collected from 4th November 9th March 2020, order assess possible spread of than official national diagnosis.Anti-SARS-CoV-2 were evaluated retrospective serum samples 234 patients with...

10.26355/eurrev_202104_25746 article EN DOAJ (DOAJ: Directory of Open Access Journals) 2021-04-01

Abstract Chronic Obstructive Pulmonary Diseases (COPDs) constitute a social problem of widespread interest. These diseases increase slowly and constantly. Air pollution its impact on public health continually repropose certain absolute priorities, such as the pin‐pointing strategies to control sources, planning observational studies epidemic control. This work shows that climate marked by always windy weather low humidity with chemical pollutant concentrations (Pietracupa; Molise, Italy) is...

10.1002/adic.200490080 article EN Annali di Chimica 2004-09-01

Abstract Purpose Medication poisoning is the most common method of self‐harm. Longitudinal studies incorporating pre‐ and post‐COVID‐19 pandemic data are required to describe phenomenon evaluate long‐term impact on mental health. Methods Calls Poison Control Center Policlinico Umberto I Hospital ‐ Sapienza University Rome, Italy, were analyzed retrospectively for characteristics clinical presentation cases interest from January 2018 December 2022. Results A total 756 self‐harm by medication...

10.1002/pds.5767 article EN Pharmacoepidemiology and Drug Safety 2024-02-01

Hepatitis C virus (HCV) causes neuropsychiatric disorders and quality of life impairment, especially in patients with cryoglobulinemic vasculitis (CV). Direct acting antivirals (DAAs) are effective most extrahepatic HCV diseases, but limited information exists regarding the outcome psychiatric without CV, after therapy. We aimed to evaluate outcomes, HCV-patients before successful DAA therapy.We prospectively studied DAA-treated HCV-patients, stratified into presence (CV) or absence CV...

10.1007/s10067-021-05877-3 article EN cc-by Clinical Rheumatology 2021-08-19
Coming Soon ...